BACKGROUND: Lung adenocarcinomas can be distinguished by identifying mutated driver
oncogenes, including epidermal growth factor receptor (EGFR) and KRAS. Mutations in …

Background The prognostic and predictive value of KRAS mutations in patients with lung
cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient …

Introduction Although classic sensitizing mutations of epidermal growth factor receptor
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …

Background/Aim: Gefitinib and erlotinib were shown to be particularly effective in a clinically
selected subpopulation of non-small cell lung cancer patients (NSCLC): adenocarcinoma …

Background Somatic mutations in the gene for the epidermal growth factor receptor (EGFR)
are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase …

Clinical implications of KRAS mutations in advanced non-small cell lung cancer remain
unclear. We retrospectively evaluated the prognostic and predictive value of KRAS …

Background Oncogenic gene mutations observed in lung adenocarcinomas, such as
epidermal growth factor receptor (EGFR) and KRAS, have some predictive value for …

Screening for EGFR and KRAS mutations in patients with lung adenocarcinomas can be
used to predict the patient's response to EGFR tyrosine kinase inhibitors, but there is a lack …

The potential clinical impact of KRAS and epidermal growth factor receptor (EGFR)
mutations has been investigated in lung adenocarcinomas; however, their prognostic value …

Background We performed this retrospective study to identify the prevalence of KRAS
mutation in Chinese populations and make a comprehensive investigation of the …